Non-Small Cell Lung Cancer (NSCLC)WEAR-LUNGNCT07733492
Rehabilitation With Wearable Monitors for Post-Lung Cancer Surgery
A study testing Wireless Wearable Vital Sign and Activity Monitor, Digital Postoperative Rehabilitation Program and Standard Postoperative Rehabilitation Education in people with Non-Small Cell Lung Cancer (NSCLC) and Rehabilitation, run by West China Hospital at 1 site in China.
Trial summary
This is a prospective, open-label, parallel-group, 1:1 randomized controlled trial evaluating whether a wireless wearable mobile monitoring device combined with a digital rehabilitation program improves pulmonary function at 90 days postoperatively in patients undergoing curative-intent lobectomy or segmentectomy for… Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- Non-Small Cell Lung Cancer (NSCLC), Rehabilitation, Thoracic Surgery
- What is being tested?
- Wireless Wearable Vital Sign and Activity Monitor, Digital Postoperative Rehabilitation Program and Standard Postoperative Rehabilitation Education
- Type of treatment
- Medical device, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 126 participants
- Where
- 1 siteChina
- Study dates
- 31 Aug 2026to 31 Aug 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥18 and ≤85 years
- Histopathologically confirmed primary non-small cell lung cancer (NSCLC) who have undergone elective curative-intent lobectomy or segmentectomy
- Planned discharge between postoperative day 2 and day 7, and judged by the investigator to be clinically stable and suitable for home-based rehabilitation
- Able to operate a smartphone application and wearable devices independently or with caregiver assistance
- Willing and able to provide written informed consent
Who cannot join
- Pre-existing long-term home oxygen therapy, or severe resting respiratory dysfunction
- Concurrent severe, uncontrolled cardiovascular disease, severe hepatic insufficiency, or severe renal insufficiency
- Other diseases or conditions that significantly affect motor function or compliance
- Known or suspected contact allergy to medical adhesives or materials used in the wearable devices
- Any other condition that, in the investigator's judgment, makes the subject unsuitable for participation
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
West China Hospital
Chengdu, Sichuan, 610041
Xuelei ma, 18708305692, drmaxuelei@gmail.com
Hu Liao, Professor
About this study
Official title: A Clinical Trial of Postoperative Rehabilitation for Non-Small Cell Lung Cancer Based on Wireless Wearable Mobile Monitoring Devices
This is a prospective, open-label, parallel-group, 1:1 randomized controlled trial evaluating whether a wireless wearable mobile monitoring device combined with a digital rehabilitation program improves pulmonary function at 90 days postoperatively in patients undergoing curative-intent lobectomy or segmentectomy for non-small cell lung cancer (NSCLC).
Eligible participants will be randomized to either the intervention group or the control group. Both groups receive standard postoperative rehabilitation education. The intervention group additionally receives a wearable device (chest patch or wristband) for continuous monitoring of SpO₂, heart rate, respiratory rate, and physical activity, along with a smartphone-based digital rehabilitation program including individualized exercise prescriptions (aerobic, resistance, and inspiratory muscle training), daily symptom diaries, and remote feedback with threshold-triggered alerts for up to 90 days after discharge. The control group receives standard rehabilitation education with routine follow-up.
Read more
The primary endpoint is the between-group difference in FEV1% predicted at postoperative day 90, analyzed using ANCOVA adjusted for baseline FEV1% predicted. Secondary endpoints include FVC% predicted, 6-minute walk distance, daily step count, SpO₂ <90% time burden, quality of life (EORTC QLQ-C30/LC13, mMRC), 90-day readmission and emergency visit rates, and safety outcomes.
A total of 126 participants (63 per group) will be enrolled. The study is being conducted at West China Hospital of Sichuan University from June 2026 to October 2027.
Read the detailed description
Study Design
This is a prospective, single-center, parallel-group, 1:1 randomized controlled superiority trial conducted at West China Hospital of Sichuan University. Enrollment is planned from June 2026 to August 2027, with final data analysis by October 2027. The study protocol has been approved by the local ethics committee (Approval No. 2025-2643, dated December 30, 2025).
Study Population
We will enroll 126 patients aged 18-85 years with histopathologically confirmed primary NSCLC who have undergone elective curative-intent lobectomy or segmentectomy. Eligible participants must be planned for discharge between postoperative days 2-7, clinically stable for home-based rehabilitation, and able to operate a smartphone and wearable devices independently or with caregiver assistance.
Randomization and Blinding
Participants are randomized 1:1 using a central web-based block randomization system. This is a single-blind trial: participants and rehabilitation instructors are aware of group assignment, but outcome assessors (pulmonary function technicians, 6MWD operators) and statisticians are blinded to group allocation.
Intervention
Control group receives standard postoperative rehabilitation education, including breathing exercises and progressive walking recommendations, with routine follow-up at 1 month and 3 months.
Intervention group receives, in addition to standard education: (1) a wireless wearable patch or wristband for continuous monitoring of SpO₂, single-lead ECG, respiratory rate, and activity data; (2) a smartphone-based digital rehabilitation program with individualized exercise prescriptions (aerobic, resistance, and inspiratory muscle training) and daily symptom diaries; and (3) remote feedback and threshold-triggered alerts (e.g., SpO₂ <90% for >1 minute) with graded clinical responses.
Follow-up and Assessments
The observation period spans from discharge to postoperative day 90. Assessments include pulmonary function tests (FEV1%, FVC%, FEV1/FVC), 6-minute walk distance, quality of life (EORTC QLQ-C30/LC13, mMRC), continuous physiological monitoring (intervention group only), adherence metrics, and healthcare utilization (readmissions, ED visits, complications).
Primary Endpoint
The primary endpoint is the FEV1% predicted at postoperative day 90 (±14 days), analyzed by ANCOVA with baseline FEV1% predicted as covariate.
Sample Size
With two-sided α=0.05, 80% power, an expected between-group difference of 7% in FEV1% predicted, and a pooled standard deviation of 12%, 53 participants per group are required. Accounting for 18% dropout, the final sample size is 126 (63 per group).
Statistical Analysis
Primary analysis will be performed on the intention-to-treat population using ANCOVA. Secondary continuous endpoints will be analyzed using ANCOVA or repeated-measures ANOVA; categorical endpoints using chi-square or Fisher's exact test. Safety outcomes will be summarized descriptively. A two-sided p-value <0.05 is considered statistically significant.
Safety and Data Quality
Adverse events are graded per CTCAE v5.0. Serious adverse events are reported within 24 hours. All study personnel follow standardized operating procedures, and electronic data capture with dual entry and logic checks ensures data quality.
Ethics and Dissemination
The study is conducted in accordance with the Declaration of Helsinki and Chinese regulations. Written informed consent will be obtained from all participants. Results will be published regardless of outcome.
- Being tested
- Wireless Wearable Vital Sign and Activity Monitor, Digital Postoperative Rehabilitation Program, Standard Postoperative Rehabilitation Education
- Keywords
- Non-Small Cell Lung Cancer (NSCLC), Rehabilitation, Thoracic Surgery
- Medical subject headings
- Carcinoma, Non-Small-Cell Lung
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Wireless Wearable Vital Sign and Activity MonitorDevice
Wireless wearable chest patchs or wristband integrating SpO₂, single-lead ECG, respiratory rate, and accelerometer sensors for continuous monitoring of vital signs and physical activity during daily living.
Digital Postoperative Rehabilitation ProgramBehavioural
A 90-day home-based digital rehabilitation program delivered via smartphone application, including individualized exercise prescriptions (aerobic walking, resistance training with elastic bands, inspiratory muscle training), daily symptom diaries (cough, sputum, dyspnea), and remote feedback with threshold-triggered alerts and weekly telehealth follow-ups.
Standard Postoperative Rehabilitation EducationOther
Standardized verbal and written postoperative rehabilitation education including breathing exercises (abdominal breathing, pursed-lip breathing, effective coughing), progressive walking recommendations, and routine outpatient follow-up at 1 month and 3 months per institutional practice.
| Study group | Role | What they receive |
|---|---|---|
| Digital Rehabilitation with Wearable Monitoring | Experimental | Participants receive standard postoperative rehabilitation education plus a wireless wearable mobile monitoring and digital rehabilitation program for 90 days post-discharge. This includes: (1) continuous vital sign and activity monitoring via a wearable chest patch or wristband (SpO₂, heart rate, respiratory rate, physical activity); (2) individualized digital rehabilitation prescriptions (aerobic, resistance, and inspiratory muscle training) with daily symptom diaries; and (3) remote feedback with threshold-triggered graded responses. Receives: Device: Wireless Wearable Vital Sign and Activity Monitor; Behavioral: Digital Postoperative Rehabilitation Program |
| Standard Postoperative Rehabilitation | Active comparator | Participants receive standard postoperative rehabilitation education, including breathing exercises (abdominal breathing, pursed-lip breathing, effective coughing), progressive walking recommendations, and routine follow-up visits at 1 month and 3 months. No wearable monitoring or digital rehabilitation prescription is provided. Receives: Other: Standard Postoperative Rehabilitation Education |
What is being measured
The primary outcome is the main question the study is designed to answer.
FEV1% Predicted at Postoperative Day 90
Forced expiratory volume in 1 second (FEV1) as a percentage of predicted value, measured by spirometry according to ATS/ERS standards. The best value from at least three acceptable maneuvers is recorded. The between-group difference is analyzed using ANCOVA with baseline FEV1% predicted as covariate.
Measured: Postoperative day 90 (±14 days)
Secondary outcomes (17)
FVC% Predicted at Postoperative Day 90
Forced vital capacity (FVC) as a percentage of predicted value, measured by spirometry at postoperative day 90.
Measured: Postoperative day 90 (±14 days)
FEV1/FVC Ratio at Postoperative Day 90
Ratio of FEV1 to FVC, measured by spirometry at postoperative day 90.
Measured: Postoperative day 90 (±14 days)
6-Minute Walk Distance at Postoperative Day 90
Total walking distance (in meters) during a 6-minute walk test performed in a 30-meter corridor by a blinded assessor according to standardized protocols.
Measured: Postoperative day 90 (±14 days)
Daily Step Count
Mean daily step count derived from the accelerometer of the wearable device, calculated as the average over the 90-day post-discharge period.
Measured: Continuous from discharge to postoperative day 90 (intervention group only)
Moderate-to-Vigorous Physical Activity (MVPA) Duration
Daily minutes of moderate-to-vigorous physical activity derived from the accelerometer of the wearable device.
Measured: Continuous from discharge to postoperative day 90 (intervention group only)
Time Proportion with SpO₂ Below 90%
Percentage of total monitoring time with SpO₂ <90% during the 90-day post-discharge period.
Measured: Continuous from discharge to postoperative day 90 (intervention group only)
Mean SpO₂ and Lowest SpO₂
Mean oxygen saturation (SpO₂) and the lowest recorded SpO₂ value during the 90-day post-discharge period.
Measured: Continuous from discharge to postoperative day 90 (intervention group only)
EORTC QLQ-C30 Global Health Status Score
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) global health status and functional scale scores at postoperative day 90, compared to baseline.
Measured: Baseline (pre-discharge) and postoperative day 90
EORTC QLQ-LC13 Lung Cancer Module Scores
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13-item module (EORTC QLQ-LC13) domain scores assessing lung cancer-specific symptoms at postoperative day 90.
Measured: Baseline (pre-discharge) and postoperative day 90
mMRC Dyspnea Scale Score
Modified Medical Research Council (mMRC) dyspnea scale score (0-4) assessed at postoperative day 90.
Measured: Baseline (pre-discharge) and postoperative day 90
90-Day Unplanned Readmission Rate
Proportion of participants with any unplanned all-cause hospital readmission within 90 days after the index surgery.
Measured: Within 90 days after surgery
90-Day Emergency Department Visit Rate
Proportion of participants with any unplanned emergency department visit within 90 days after the index surgery.
Measured: Within 90 days after surgery
90-Day Pulmonary Complication Rate
Proportion of participants developing pulmonary complications (e.g., pneumonia, atelectasis, prolonged air leak) within 90 days after surgery.
Measured: Within 90 days after surgery
Days Alive and Out of Hospital Within 90 Days
Number of days alive and not hospitalized (in hospital or rehabilitation facility) during the 90-day post-surgery period.
Measured: Within 90 days after surgery
Wearable Device Adherence Rate
Proportion of valid wear days, defined as days with ≥20 hours of monitoring data from the wearable device during the 90-day post-discharge period.
Measured: From discharge to postoperative day 90 (intervention group only)
Incidence of Device-Related Skin Reactions
Proportion of participants experiencing device-related skin reactions (e.g., erythema, pruritus, rash, contact dermatitis, skin breakdown) graded by severity per CTCAE v5.0.
Measured: From discharge to postoperative day 90
Incidence of Any Adverse Event and Serious Adverse Event
Proportion of participants experiencing at least one adverse event (AE) or serious adverse event (SAE) during the study period. AEs are graded per CTCAE v5.0; SAEs are defined per ICH criteria.
Measured: From enrollment through postoperative day 90
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jul 2026
- Study start31 Aug 2026 (estimated)
- Primary completion31 Aug 2028 (estimated)
- Study completion31 Aug 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Non-Small Cell Lung Cancer (NSCLC)Studies of the same condition, open and under way.
- More trials run by West China HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 126 participants (estimated)
Sponsor and investigators
- Lead sponsor
- West China Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Xuelei Ma MD, West China Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07733492
- Sponsor's protocol ID
- 2025(2643)
- Acronym
- WEAR-LUNG
- Status last verified
- Aug 2026
- First submitted
- 24 Jul 2026
- Last updated
- 2 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Clinical Trial of Postoperative Rehabilitation for Non-Small Cell Lung Cancer Based on Wireless Wearable Mobile Monitoring Devices
- ClinicalTrials.gov ID
- NCT07733492
- Acronym / sponsor ID
- WEAR-LUNG / 2025(2643)
- Keywords
- Non-Small Cell Lung Cancer (NSCLC), Rehabilitation, Thoracic Surgery
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 126 participants (estimated)
- Lead sponsor
- West China HospitalUniversity, hospital or other
- Study start
- 31 Aug 2026 (estimated)
- Primary completion
- 31 Aug 2028 (estimated)
- Study completion
- 31 Aug 2028 (estimated)
- First posted
- 29 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a prospective, open-label, parallel-group, 1:1 randomized controlled trial evaluating whether a wireless wearable mobile monitoring device combined with a digital rehabilitation program improves pulmonary function at 90 days postoperatively in patients undergoing curative-intent lobectomy or segmentectomy for non-small cell lung cancer (NSCLC).
Eligible participants will be randomized to either the intervention group or the control group. Both groups receive standard postoperative rehabilitation education. The intervention group additionally receives a wearable device (chest patch or wristband) for continuous monitoring of SpO₂, heart rate, respiratory rate, and physical activity, along with a smartphone-based digital rehabilitation program including individualized exercise prescriptions (aerobic, resistance, and inspiratory muscle training), daily symptom diaries, and remote feedback with threshold-triggered alerts for up to 90 days after discharge. The control group receives standard rehabilitation education with routine follow-up.
The primary endpoint is the between-group difference in FEV1% predicted at postoperative day 90, analyzed using ANCOVA adjusted for baseline FEV1% predicted. Secondary endpoints include FVC% predicted, 6-minute walk distance, daily step count, SpO₂ <90% time burden, quality of life (EORTC QLQ-C30/LC13, mMRC), 90-day readmission and emergency visit rates, and safety outcomes.
A total of 126 participants (63 per group) will be enrolled. The study is being conducted at West China Hospital of Sichuan University from June 2026 to October 2027.
Detailed description
Study Design
This is a prospective, single-center, parallel-group, 1:1 randomized controlled superiority trial conducted at West China Hospital of Sichuan University. Enrollment is planned from June 2026 to August 2027, with final data analysis by October 2027. The study protocol has been approved by the local ethics committee (Approval No. 2025-2643, dated December 30, 2025).
Study Population
We will enroll 126 patients aged 18-85 years with histopathologically confirmed primary NSCLC who have undergone elective curative-intent lobectomy or segmentectomy. Eligible participants must be planned for discharge between postoperative days 2-7, clinically stable for home-based rehabilitation, and able to operate a smartphone and wearable devices independently or with caregiver assistance.
Randomization and Blinding
Participants are randomized 1:1 using a central web-based block randomization system. This is a single-blind trial: participants and rehabilitation instructors are aware of group assignment, but outcome assessors (pulmonary function technicians, 6MWD operators) and statisticians are blinded to group allocation.
Intervention
Control group receives standard postoperative rehabilitation education, including breathing exercises and progressive walking recommendations, with routine follow-up at 1 month and 3 months.
Intervention group receives, in addition to standard education: (1) a wireless wearable patch or wristband for continuous monitoring of SpO₂, single-lead ECG, respiratory rate, and activity data; (2) a smartphone-based digital rehabilitation program with individualized exercise prescriptions (aerobic, resistance, and inspiratory muscle training) and daily symptom diaries; and (3) remote feedback and threshold-triggered alerts (e.g., SpO₂ <90% for >1 minute) with graded clinical responses.
Follow-up and Assessments
The observation period spans from discharge to postoperative day 90. Assessments include pulmonary function tests (FEV1%, FVC%, FEV1/FVC), 6-minute walk distance, quality of life (EORTC QLQ-C30/LC13, mMRC), continuous physiological monitoring (intervention group only), adherence metrics, and healthcare utilization (readmissions, ED visits, complications).
Primary Endpoint
The primary endpoint is the FEV1% predicted at postoperative day 90 (±14 days), analyzed by ANCOVA with baseline FEV1% predicted as covariate.
Sample Size
With two-sided α=0.05, 80% power, an expected between-group difference of 7% in FEV1% predicted, and a pooled standard deviation of 12%, 53 participants per group are required. Accounting for 18% dropout, the final sample size is 126 (63 per group).
Statistical Analysis
Primary analysis will be performed on the intention-to-treat population using ANCOVA. Secondary continuous endpoints will be analyzed using ANCOVA or repeated-measures ANOVA; categorical endpoints using chi-square or Fisher's exact test. Safety outcomes will be summarized descriptively. A two-sided p-value <0.05 is considered statistically significant.
Safety and Data Quality
Adverse events are graded per CTCAE v5.0. Serious adverse events are reported within 24 hours. All study personnel follow standardized operating procedures, and electronic data capture with dual entry and logic checks ensures data quality.
Ethics and Dissemination
The study is conducted in accordance with the Declaration of Helsinki and Chinese regulations. Written informed consent will be obtained from all participants. Results will be published regardless of outcome.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Digital Rehabilitation with Wearable Monitoring | Experimental | Device: Wireless Wearable Vital Sign and Activity Monitor, Behavioral: Digital Postoperative Rehabilitation ProgramParticipants receive standard postoperative rehabilitation education plus a wireless wearable mobile monitoring and digital rehabilitation program for 90 days post-discharge. This includes: (1) continuous vital sign and activity monitoring via a wearable chest patch or wristband (SpO₂, heart rate, respiratory rate, physical activity); (2) individualized digital rehabilitation prescriptions (aerobic, resistance, and inspiratory muscle training) with daily symptom diaries; and (3) remote feedback with threshold-triggered graded responses. |
| Standard Postoperative Rehabilitation | Active comparator | Other: Standard Postoperative Rehabilitation EducationParticipants receive standard postoperative rehabilitation education, including breathing exercises (abdominal breathing, pursed-lip breathing, effective coughing), progressive walking recommendations, and routine follow-up visits at 1 month and 3 months. No wearable monitoring or digital rehabilitation prescription is provided. |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Age ≥18 and ≤85 years
- Histopathologically confirmed primary non-small cell lung cancer (NSCLC) who have undergone elective curative-intent lobectomy or segmentectomy
- Planned discharge between postoperative day 2 and day 7, and judged by the investigator to be clinically stable and suitable for home-based rehabilitation
- Able to operate a smartphone application and wearable devices independently or with caregiver assistance
- Willing and able to provide written informed consent
Key exclusion criteria (5 listed)
- Pre-existing long-term home oxygen therapy, or severe resting respiratory dysfunction
- Concurrent severe, uncontrolled cardiovascular disease, severe hepatic insufficiency, or severe renal insufficiency
- Other diseases or conditions that significantly affect motor function or compliance
- Known or suspected contact allergy to medical adhesives or materials used in the wearable devices
- Any other condition that, in the investigator's judgment, makes the subject unsuitable for participation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Wireless Wearable Vital Sign and Activity MonitorWireless wearable chest patchs or wristband integrating SpO₂, single-lead ECG, respiratory rate, and accelerometer sensors for continuous monitoring of vital signs and physical activity during daily living. | Device | Digital Rehabilitation with Wearable Monitoring |
| Digital Postoperative Rehabilitation ProgramA 90-day home-based digital rehabilitation program delivered via smartphone application, including individualized exercise prescriptions (aerobic walking, resistance training with elastic bands, inspiratory muscle training), daily symptom diaries (cough, sputum, dyspnea), and remote feedback with threshold-triggered alerts and weekly telehealth follow-ups. | Behavioural | Digital Rehabilitation with Wearable Monitoring |
| Standard Postoperative Rehabilitation EducationStandardized verbal and written postoperative rehabilitation education including breathing exercises (abdominal breathing, pursed-lip breathing, effective coughing), progressive walking recommendations, and routine outpatient follow-up at 1 month and 3 months per institutional practice. | Other | Standard Postoperative Rehabilitation |
Primary outcome
FEV1% Predicted at Postoperative Day 90
Time frame: Postoperative day 90 (±14 days)
Forced expiratory volume in 1 second (FEV1) as a percentage of predicted value, measured by spirometry according to ATS/ERS standards. The best value from at least three acceptable maneuvers is recorded. The between-group difference is analyzed using ANCOVA with baseline FEV1% predicted as covariate.
17 secondary outcomes
FVC% Predicted at Postoperative Day 90
Time frame: Postoperative day 90 (±14 days)
FEV1/FVC Ratio at Postoperative Day 90
Time frame: Postoperative day 90 (±14 days)
6-Minute Walk Distance at Postoperative Day 90
Time frame: Postoperative day 90 (±14 days)
Daily Step Count
Time frame: Continuous from discharge to postoperative day 90 (intervention group only)
Moderate-to-Vigorous Physical Activity (MVPA) Duration
Time frame: Continuous from discharge to postoperative day 90 (intervention group only)
Time Proportion with SpO₂ Below 90%
Time frame: Continuous from discharge to postoperative day 90 (intervention group only)
Mean SpO₂ and Lowest SpO₂
Time frame: Continuous from discharge to postoperative day 90 (intervention group only)
EORTC QLQ-C30 Global Health Status Score
Time frame: Baseline (pre-discharge) and postoperative day 90
EORTC QLQ-LC13 Lung Cancer Module Scores
Time frame: Baseline (pre-discharge) and postoperative day 90
mMRC Dyspnea Scale Score
Time frame: Baseline (pre-discharge) and postoperative day 90
90-Day Unplanned Readmission Rate
Time frame: Within 90 days after surgery
90-Day Emergency Department Visit Rate
Time frame: Within 90 days after surgery
90-Day Pulmonary Complication Rate
Time frame: Within 90 days after surgery
Days Alive and Out of Hospital Within 90 Days
Time frame: Within 90 days after surgery
Wearable Device Adherence Rate
Time frame: From discharge to postoperative day 90 (intervention group only)
Incidence of Device-Related Skin Reactions
Time frame: From discharge to postoperative day 90
Incidence of Any Adverse Event and Serious Adverse Event
Time frame: From enrollment through postoperative day 90
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Non-Small Cell Lung Cancer (NSCLC)
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Wireless Wearable Vital Sign and Activity Monitor, Digital Postoperative Rehabilitation Program and Standard Postoperative Rehabilitation Education in people with Non-Small Cell Lung Cancer (NSCLC) and Rehabilitation, run by West China Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 2 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Xuelei ma (+8618708305692, drmaxuelei@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
FEV1% Predicted at Postoperative Day 90 (time frame: Postoperative day 90 (±14 days)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Sep 2026.